At a glance
ClinicalIndex Comparison Record- ✓Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease, or stage I primary mediastinal (thymic) DLBCL
- ✓WHO classification subtypes: DLBCL (centroblastic, immunoblastic, T-cell/histiocyte rich, anaplastic), mediastinal (thymic) large B-cell lymphoma, or intravascular large B-cell lymphoma
- ✓Fresh (frozen) tumor biopsy material available or attempted (minimum four 16-gauge needle cores or equivalent)
- ✓Age ≥18 years
- ✕Prior low-grade lymphoma, transformed lymphoma, or low-grade lymphoma in bone marrow
- ✕Prior cytotoxic chemotherapy or rituximab (unless prior limited field radiation or short glucocorticoid course <10 days for urgent local complications)
- ✕Chemotherapy for any prior malignancy
- ✕Known HIV infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
In Brief
A Phase 3 clinical trial evaluating rituximab, cyclophosphamide, and 6 other interventions for Large B Cell Lymphoma. Completed, enrolled 524 participants across 47 sites.
Detailed Summary
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.
Study Details
Timeline
Interventions
IV
IV
IV or CIVI
IV or CIVI
oral
CIVI
IV
IV